A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers
Erin George(University of Pennsylvania), Fiona Simpkins(The Wistar Institute)
Cited by 71
Related Papers
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in <i>BRCA</i> -Mutant Ovarian Cancer Models
|Clinical Cancer Research|2016|292
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
|iScience|2024|11